Literature DB >> 10996018

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

W Maruyama1, T Yamamoto, K Kitani, M C Carrillo, M Youdim, M Naoi.   

Abstract

A potent inhibitor of type B monoamine oxidase, (-)deprenyl, is known to protect or rescue dying neurons, independent of inhibition of the enzyme activity. After long term administration to rodents, a propargylamine structurally related to (-)deprenyl, (R)(+)-N-propargyl-1-aminoindan (rasagiline) increased the activities of anti-oxidative enzymes, superoxide dismutase and catalase. Rasagiline protected in vitro dopamine cells from apoptosis induced by oxidative stress or neurotoxins. The mechanism of the anti-apoptotic effect was studied by in vitro experiments using human dopaminergic neuroblastoma, SH-SY5Y cells. Peroxynitrite-generating N-morpholino sydonimine (SIN-1) induced apoptosis in SH-SY5Y cells via disruption of mitochondrial membrane potential (DeltaPsim), followed by caspase 3 activation. Rasagiline prevented the loss of DeltaPsim, the initial step to apoptosis, and also following caspase 3-activation and DNA fragmentation. The results suggest that rasagiline may interact with the specific molecule in the mitochondria and suppress the death signal transduction. By the anti-apoptotic function, rasagiline may rescue or protect declining neurons in aging and neurodegenerative disorders, such as Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996018     DOI: 10.1016/s0047-6374(00)00144-5

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  13 in total

Review 1.  Polycyclic compounds: ideal drug scaffolds for the design of multiple mechanism drugs?

Authors:  Cornelis J Van der Schyf; Werner J Geldenhuys
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

2.  Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.

Authors:  Z Speiser; A Mayk; L Litinetsky; T Fine; A Nyska; E Blaugrund; S Cohen
Journal:  J Neural Transm (Vienna)       Date:  2006-12-21       Impact factor: 3.575

Review 3.  Transcriptional regulation and multiple functions of MAO genes.

Authors:  Jean C Shih; Jason Boyang Wu; Kevin Chen
Journal:  J Neural Transm (Vienna)       Date:  2011-02-27       Impact factor: 3.575

Review 4.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

Review 5.  Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.

Authors:  Éva Szökő; Tamás Tábi; Peter Riederer; László Vécsei; Kálmán Magyar
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

Review 6.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

7.  Peroxynitrite induces neuronal cell death in aging and age-associated disorders: A review.

Authors:  W Maruyama; Y Kato; T Yamamoto; K Oh-Hashi; Y Hashizume; M Naoi
Journal:  J Am Aging Assoc       Date:  2001-01

Review 8.  Neuroprotective strategies in Parkinson's disease : an update on progress.

Authors:  Silvia Mandel; Edna Grünblatt; Peter Riederer; Manfred Gerlach; Yona Levites; Moussa B H Youdim
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Disease-Modifying Drugs in Parkinson's Disease.

Authors:  Ariane Park; Mark Stacy
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

10.  Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease.

Authors:  Bradley J Robottom
Journal:  Patient Prefer Adherence       Date:  2011-01-20       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.